Scilex Holding Company Form 8-K Summary
Business Context and Reporting Period
Scilex Holding Company filed a Form 8-K dated August 31, 2023, reporting events beginning August 27, 2023. The company is majority-owned by Sorrento Therapeutics, Inc., which, together with Scintilla Pharmaceuticals, Inc., commenced Chapter 11 proceedings on February 13, 2023. Scilex is not a debtor in those proceedings.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics.
Material Changes and Corporate Events
- On August 27, 2023, Tien-Li Lee, M.D. resigned from Scilex’s board, all board committees, and director or officer positions at company subsidiaries. The filing states the resignation was not due to a dispute or disagreement.
- On August 27, 2023, Henry Ji, Ph.D. was removed as a director by written consent of Sorrento’s chief restructuring officer, acting for Sorrento as majority voting shareholder.
- Dr. Ji resigned from his executive officer and subsidiary director or officer positions, effective upon closing of the Oramed transaction.
- Jaisim Shah announced his retirement from the board, board committees, Chief Executive Officer and President positions, and subsidiary positions, effective upon closing of the transaction. The filing states the retirement was not due to a dispute or disagreement.
- Laura J. Hamill, Dorman Followwill, and David Lemus resigned from board, committee, and subsidiary positions, with effectiveness contingent on closing of the transaction. The filing states these resignations were not due to disputes or disagreements.
Transaction, Outlook, Risks, and Unusual Items
Sorrento entered into a stalking horse stock purchase agreement with Oramed Pharmaceuticals Inc., as amended, covering 59,726,737 Scilex common shares, 29,057,096 Series A preferred shares, warrants exercisable for 2,245,309 common shares, and an option for up to 2,259,058 additional common shares held in abeyance for certain Sorrento warrant holders.
The Bankruptcy Court approved the Oramed transaction on August 30, 2023. Scilex stated that the actual closing date was not known, but expected closing on or before September 30, 2023, the outside closing date under the agreement. The effectiveness of several executive and director departures is contingent upon closing.
Important Facts for Investors to Verify
- Whether and when the Oramed transaction ultimately closed.
- The final ownership and voting structure of Scilex following the transaction.
- The identities and authority of the post-closing board and executive officers.
- Any subsequent disclosures regarding Sorrento’s bankruptcy, the transaction, or related ownership and governance effects.
- Financial performance, liquidity, debt, and operating results, which are not provided in this filing.